Farallon Capital Management 13F: Adds $62M to GRAIL (GRAL) Stake
Farallon Capital Management grew its position in GRAIL, Inc. by nearly 39% during the reporting period.
Reviewed by automated data checks against the source filing. How we make and check alerts
Farallon Capital Management added 911,000 shares to its stake in GRAIL, Inc. ($GRAL), a 38.89% increase, according to a 13F filing with the SEC dated May 15, 2026. It reported 3,253,684 shares worth $222.13 million at the end of the quarter.
Since the filing, $GRAL is up 12.6% after 1 week, up 0.3% after 1 month and up 97.5% to date (from the $59.65 close on May 15, 2026).
Find the original: Farallon Capital Management 13F filings on SEC EDGAR
GRAL
GRAIL, Inc.
Key Points
- Farallon Capital Management boosted its stake in GRAIL, Inc. by 38.9%, adding 911,000 shares to bring its total holding to 3,253,684 shares valued at roughly $222.1 million.
- Shares of GRAIL trade near $68.27, sitting below its 50-day moving average of $74.68 while maintaining a market capitalization of about $4.82 billion.
- Wall street firms keep a consensus buy outlook on the healthcare diagnostics firm, backed by a mean analyst price target of $82.40 across ten covering opinions.
Get $GRAL trade alerts by text
We text you when insiders, Congress or big funds trade $GRAL. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated GRAIL, Inc. alert may contain errors. Disclosures
Farallon Capital Expands Position in GRAIL
Farallon Capital Management lifted its investment in GRAIL, Inc. GRAL by 38.9% during the period ended May 15, 2026, according to a Form 13F filing with the Securities and Exchange Commission. The fund added 911,000 shares to its portfolio, bringing its total ownership to 3,253,684 shares. At the close of the reporting window, that stake carried an estimated value of $222.1 million. This increase follows other notable activity by the firm, including a prior large-scale addition in CG Oncology earlier in the year.
GRAIL Stock and Market Context
Shares of GRAIL changed hands around $68.27 recently, giving the healthcare diagnostics developer a market capitalization of $4.82 billion. The equity trades below its 50-day moving average of $74.68 and sits above its 200-day moving average near $72.29. Investors should note that the stock has seen a wide trading band over the past year, moving between a low of $41.50 and a high of $118.84.
Wall Street Analyst Updates
Several research firms have adjusted their views on the diagnostics provider in recent months. On September 17, 2026, RBC Capital started coverage with a sector perform rating and an $84.00 target. Baird kept an outperform rating on September 22, 2026, adjusting its target to $118.00. Mizuho kept a neutral stance on September 25, 2026, with a $100.00 target. Canaccord Genuity maintained a buy rating on September 28, 2026, moving its target to $150.00. Guggenheim kept a buy rating on October 1, 2026, with a target of $155.00, while UBS set its target at $175.00 alongside a buy rating on October 2, 2026. Morgan Stanley maintained an equal-weight rating on October 13, 2026, while setting a target of $120.00, and TD Cowen lifted its target to $180.00 while keeping a buy rating.
Inside the Business Operations
GRAIL is a commercial-stage healthcare company based in Menlo Park, California, focused on multi-cancer early detection testing and services. The company provides the Galleri screening test for asymptomatic individuals over fifty, alongside diagnostic aids and precision oncology platforms for disease prognostication and recurrence monitoring. These offerings support clinical research and therapy development across the healthcare sector.
What to Watch at GRAIL, Inc.
Institutional filings like this one provide a look at portfolio adjustments from past months and may not reflect current trading activity today. Market participants will likely monitor the company's next scheduled financial report on November 11, 2026, for further updates on revenue growth and clinical progress.
Related Filing Alerts
Source: Farallon Capital Management's 13F filing on $GRAL (May 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Farallon Capital Management 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts